Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 19;9(5):103.
doi: 10.3390/biology9050103.

Clinical Features of Parkinson's Disease: The Evolution of Critical Symptoms

Affiliations
Review

Clinical Features of Parkinson's Disease: The Evolution of Critical Symptoms

Csaba Váradi. Biology (Basel). .

Abstract

Parkinson's disease (PD) is a multi-attribute neurodegenerative disorder combining motor and nonmotor symptoms without well-defined diagnostic clinical markers. The presence of primary motor features (bradykinesia, rest tremor, rigidity and loss of postural reflexes) are the most characteristic signs of PD that are also utilized to identify patients in current clinical practice. The successful implementation of levodopa treatment revealed that nonmotor features are the main contributors of patient disability in PD, and their occurrence might be earlier than motor symptoms during disease progression. Targeted detection of prodromal PD symptoms can open up new possibilities in the identification of PD patients and provide potential patient populations for developing novel neuroprotective therapies. In this review, the evolution of critical features in PD diagnosis is described with special attention to nonmotor symptoms and their possible detection.

Keywords: Lewy body; Parkinson’s disease; clinical criteria; neurodegeneration; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflicts of interest.

Figures

Figure 1
Figure 1
The diverse nature of nonmotor symptoms affecting Parkinson’s disease (PD) patients.
Figure 2
Figure 2
Timeline of clinical signs expressed throughout PD.

References

    1. Parkinson J. An essay on the Shaking Palsy. Arch. Neurol. 1969;20:441–445. doi: 10.1001/archneur.1969.00480100117017. - DOI
    1. Kalia L.V., Lang A.E. Parkinson’s disease. Lancet. 2015;386:896–912. doi: 10.1016/S0140-6736(14)61393-3. - DOI - PubMed
    1. Mhyre T.R., Boyd J.T., Hamill R.W., Maguire-Zeiss K.A. Parkinson’s disease. Subcell Biochem. 2012;65:389–455. doi: 10.1007/978-94-007-5416-4_16. - DOI - PMC - PubMed
    1. Hirsch L., Jette N., Frolkis A., Steeves T., Pringsheim T. The Incidence of Parkinson’s Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2016;46:292–300. doi: 10.1159/000445751. - DOI - PubMed
    1. Driver J.A., Logroscino G., Gaziano J.M., Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. 2009;72:432–438. doi: 10.1212/01.wnl.0000341769.50075.bb. - DOI - PMC - PubMed

LinkOut - more resources